A proton pump inhibitor
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Tegoprazan

Item No. 33243

Technical Information
Formal Name
7-[[(4S)-5,7-difluoro-3,4-dihydro-2H-1-benzopyran-4-yl]oxy]-N,N,2-trimethyl-1H-benzimidazole-5-carboxamide
CAS Number
942195-55-3
Synonyms
  • CJ-12420
Molecular Formula
C20H19F2N3O3
Formula Weight
Purity
≥98%
A solid
λmax
220 nm
SMILES
CN(C)C(C1=CC(O[C@@H]2C3=C(F)C=C(F)C=C3OCC2)=C4C(N=C(N4)C)=C1)=O
InChi Code
InChI=1S/C20H19F2N3O3/c1-10-23-14-6-11(20(26)25(2)3)7-17(19(14)24-10)28-15-4-5-27-16-9-12(21)8-13(22)18(15)16/h6-9,15H,4-5H2,1-3H3,(H,23,24)/t15-/m0/s1
InChi Key
CLIQCDHNPDMGSL-HNNXBMFYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Product Description

    Tegoprazan is a proton pump inhibitor that inhibits H+/K+-ATPase activity in porcine gastric membrane vesicles (IC50 = 0.53 µM).1 It completely inhibits basal gastric acid secretion in pylorus-ligated rats when administered at a dose of 10 mg/kg and reduces esophageal mucosal tissue levels of myeloperoxidase (MPO), a marker of tissue damage, in a rat model of reflux esophagitis (ED50 = 5.9 mg/kg). Tegoprazan reduces ulcer area in rat models of gastric ulcers induced by naproxen, water-immersion restraint stress (WIRS), or ethanol (ED50s = 0.1, 0.1, and 1.4 mg/kg, respectively).

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kim, D.K., Lee, K.-H., Kim, S.-J., et al. Effects of tegoprazan, a novel potassium-competitive acid blocker, on rat models of gastric acid-related disease. J. Pharmacol. Exp. Ther. 369(3), 318-327 (2019).